Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Effect of Discontinuing vs Continuing Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on Days Alive and Out of the Hospital in Patients Admitted With COVID-19
Renato D. Lópes, Ariane Vieira Scarlatelli Macedo, Pedro Gabriel Melo de Barros e Silva, et al.
JAMA (2021) Vol. 325, Iss. 3, pp. 254-254
Open Access | Times Cited: 335

Showing 1-25 of 335 citing articles:

Post-acute COVID-19 syndrome
Ani Nalbandian, Kartik Sehgal, Aakriti Gupta, et al.
Nature Medicine (2021) Vol. 27, Iss. 4, pp. 601-615
Open Access | Times Cited: 4248
Drug treatments for covid-19: living systematic review and network meta-analysis
Reed Siemieniuk, Jessica Bartoszko, Dena Zeraatkar, et al.
BMJ (2020), pp. m2980-m2980
Open Access | Times Cited: 796
Long-term complications of COVID-19
Amar D. Desai, Michael P. Lavelle, Brian C. Boursiquot, et al.
AJP Cell Physiology (2021) Vol. 322, Iss. 1, pp. C1-C11
Open Access | Times Cited: 350
ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2—care pathways, treatment, and follow-up
Colin Baigent, Stephan Windecker, Daniele Andreini, et al.
European Heart Journal (2021) Vol. 43, Iss. 11, pp. 1059-1103
Open Access | Times Cited: 147
Risk factors for COVID-19 diagnosis, hospitalization, and subsequent all-cause mortality in Sweden: a nationwide study
Jonathan Bergman, Marcel Ballin, Anna Nordström, et al.
European Journal of Epidemiology (2021) Vol. 36, Iss. 3, pp. 287-298
Open Access | Times Cited: 144
Therapeutic advances in COVID-19
Naoka Murakami, Robert Hayden, Thomas Hills, et al.
Nature Reviews Nephrology (2022) Vol. 19, Iss. 1, pp. 38-52
Open Access | Times Cited: 128
Hypertension and COVID-19: Current Evidence and Perspectives
Giovanna Gallo, Valentin Calvez, Carmine Savoia
High Blood Pressure & Cardiovascular Prevention (2022) Vol. 29, Iss. 2, pp. 115-123
Open Access | Times Cited: 109
European Society of Cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 1—epidemiology, pathophysiology, and diagnosis
Colin Baigent, Stephan Windecker, Daniele Andreini, et al.
European Heart Journal (2021) Vol. 43, Iss. 11, pp. 1033-1058
Open Access | Times Cited: 107
2022 Guidelines of the Taiwan Society of Cardiology and the Taiwan Hypertension Society for the Management of Hypertension.
Tzung‐Dau Wang, Chern‐En Chiang, Ting‐Hsing Chao, et al.
PubMed (2022) Vol. 38, Iss. 3, pp. 225-325
Closed Access | Times Cited: 87
Angiotensin II Type I Receptor (AT1R): The Gate towards COVID-19-Associated Diseases
George El-Arif, Shaymaa Khazaal, Antonella Farhat, et al.
Molecules (2022) Vol. 27, Iss. 7, pp. 2048-2048
Open Access | Times Cited: 71
Therapeutics for COVID-19 and post COVID-19 complications: An update
Debdoot Basu, Vivek P. Chavda, Anita A. Mehta
Current Research in Pharmacology and Drug Discovery (2022) Vol. 3, pp. 100086-100086
Open Access | Times Cited: 68
Effect of Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Initiation on Organ Support–Free Days in Patients Hospitalized With COVID-19
Simin Aysel Florescu, Dragos Stanciu, Mihaela Zaharia, et al.
JAMA (2023) Vol. 329, Iss. 14, pp. 1183-1183
Open Access | Times Cited: 45
Discontinuation versus continuation of renin-angiotensin-system inhibitors in COVID-19 (ACEI-COVID): a prospective, parallel group, randomised, controlled, open-label trial
Axel Bauer, Michael Schreinlechner, Nikolay Sappler, et al.
The Lancet Respiratory Medicine (2021) Vol. 9, Iss. 8, pp. 863-872
Open Access | Times Cited: 94
Hospital-Free Days: A Pragmatic and Patient-centered Outcome for Trials among Critically and Seriously Ill Patients
Catherine L. Auriemma, Stephanie Parks Taylor, Michael O. Harhay, et al.
American Journal of Respiratory and Critical Care Medicine (2021) Vol. 204, Iss. 8, pp. 902-909
Open Access | Times Cited: 79
Hypertension, a Moving Target in COVID-19
Carmine Savoia, Massimo Volpe, Reinhold Kreutz
Circulation Research (2021) Vol. 128, Iss. 7, pp. 1062-1079
Open Access | Times Cited: 78
Arterial hypertension – Clinical trials update 2021
Hussam Al Ghorani, Felix Götzinger, Michael Böhm, et al.
Nutrition Metabolism and Cardiovascular Diseases (2021) Vol. 32, Iss. 1, pp. 21-31
Open Access | Times Cited: 78
Exercise Training and Cardiac Rehabilitation in COVID-19 Patients with Cardiovascular Complications: State of Art
Mariaconsiglia Calabrese, Marina Garofano, Roberta Palumbo, et al.
Life (2021) Vol. 11, Iss. 3, pp. 259-259
Open Access | Times Cited: 68
COVID-19 and kidney disease: insights from epidemiology to inform clinical practice
Viyaasan Mahalingasivam, Guobin Su, Masao Iwagami, et al.
Nature Reviews Nephrology (2022) Vol. 18, Iss. 8, pp. 485-498
Open Access | Times Cited: 65
Effect of Sotagliflozin on Total Hospitalizations in Patients With Type 2 Diabetes and Worsening Heart Failure
Michael Szarek, Deepak L. Bhatt, Philippe Gabríel Steg, et al.
Annals of Internal Medicine (2021) Vol. 174, Iss. 8, pp. 1065-1072
Open Access | Times Cited: 59
Guía práctica sobre el diagnóstico y tratamiento de la hipertensión arterial en España, 2022. Sociedad Española de Hipertensión - Liga Española para la Lucha contra la Hipertensión Arterial (SEH-LELHA)
Manuel Gorostidi, Teresa Gijón‐Conde, Àngels Sierra, et al.
Hipertensión y Riesgo Vascular (2022) Vol. 39, Iss. 4, pp. 174-194
Closed Access | Times Cited: 59
Endothelial Dysfunction in COVID-19: A Unifying Mechanism and a Potential Therapeutic Target
Pasquale Ambrosino, Ilenia Calcaterra, Marco Mosella, et al.
Biomedicines (2022) Vol. 10, Iss. 4, pp. 812-812
Open Access | Times Cited: 52
Anticoagulation in Patients With COVID-19
Michael E. Farkouh, Gregg W. Stone, Anuradha Lala, et al.
Journal of the American College of Cardiology (2022) Vol. 79, Iss. 9, pp. 917-928
Open Access | Times Cited: 51
Efficacy of Losartan in Hospitalized Patients With COVID-19–Induced Lung Injury
Michael A. Puskarich, Nicholas E. Ingraham, Lisa H. Merck, et al.
JAMA Network Open (2022) Vol. 5, Iss. 3, pp. e222735-e222735
Open Access | Times Cited: 51
Renin‐Angiotensin System Inhibitors in Patients With COVID‐19: A Meta‐Analysis of Randomized Controlled Trials Led by the International Society of Hypertension
Sonali R. Gnanenthiran, Claudio Borghi, Dylan Burger, et al.
Journal of the American Heart Association (2022) Vol. 11, Iss. 17
Open Access | Times Cited: 44
A raising dawn of pentoxifylline in management of inflammatory disorders in Covid-19
Gomaa Mostafa‐Hedeab, Hayder M. Al‐kuraishy, Ali I. Al‐Gareeb, et al.
Inflammopharmacology (2022) Vol. 30, Iss. 3, pp. 799-809
Open Access | Times Cited: 39
Page 1 - Next Page

Scroll to top